Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that topical hair lotions with 17 alpha-estradiol may reduce telogen hair loss in patients with androgenetic alopecia, though they did not lead to new hair regrowth.

This study found that 17β-estradiol was the most powerful hormone for inducing APE1/Ref-1 secretion in cultured vascular endothelial cells, with secretion occurring through exosomes dependent on estrogen receptors and intracellular calcium.

This study found that treatment with a GnRH agonist and estrogen and progestin replacement significantly improved hirsutism scores and hair growth rates in women with polycystic ovarian disease.

This study found that estetrol (E4) significantly prolonged the anagen phase and increased hair matrix keratinocyte proliferation in cultured human hair follicles, suggesting its potential as a treatment for female pattern hair loss.

This paper discusses hormonal therapy options for women with severe acne, focusing on treatment for cases that do not respond to conventional methods, but it reports no new clinical findings.

This article reviews the negative effects of androgenic disorders and highlights that newer oral contraceptives with less androgenic progestins may reduce these effects and improve compliance, but it reports no new results.

This study found that scabies was the most common skin condition among children up to 15 years old at a Karachi hospital in 2005.

Formestane is a preferred second-line treatment for advanced breast cancer in postmenopausal women because it's effective and has fewer side effects.

This trial explores whether spironolactone is more effective than cyclines for treating moderate acne in adult women, providing a potential alternative amidst concerns over antibiotic resistance.

This article discusses the use of topical estrogen therapy for androgenetic alopecia in menopausal females and reports no new clinical results.

This study found that a decrease in estradiol levels in women is associated with increased hair shedding due to weakened anchoring of telogen hairs.

This review discusses treatment options for hirsutism in women of childbearing age, focusing on the use of contraceptives, CPA, spironolactone, and third-line therapies, and reports no clinical results.

This review examines the role of hormones in acne pathogenesis, the use of hormonal therapies for treatment, and the importance of contraceptive counseling during isotretinoin therapy, but reports no new clinical results.

This study found that 17beta-estradiol enhanced allergy responses in certain age groups of female mice and inhibited thymus involution and regeneration after contact hypersensitivity.

This review found that combined oral contraceptives and spironolactone are effective treatments for adult acne in women, but noted that oral contraceptives increase the risk of venous thromboembolism and require individual risk assessment before use.

This review updates dermatologists on both FDA-approved and off-label hormonal therapies, including combined oral contraceptives, clascoterone, and spironolactone, used for acne treatment, providing insights into emerging approaches for managing the condition.

This review discusses the role of estrogens in hair follicle cycling and the skin, highlighting the need for more research on estrogen signaling pathways and their interactions with other factors in hair biology.

In this study, daily administration of 100mg DHEA for 16 weeks in women with adequate ovarian reserve did not modify metabolic or reproductive variables, apart from increased antral follicular count and anti-Müllerian hormone levels.

This study concluded that both vaginal TEST and Estring may be effective for treating vaginal dryness in breast cancer patients on aromatase inhibitors, with adverse events being rare and manageable.

This review discusses various sex hormones and related compounds, including estrogens and anabolic steroids, but reports no new findings; it highlights existing literature from 2014 regarding their use and effects.

This trial will compare the effectiveness of spironolactone to doxycycline for treating acne in adult females, potentially offering an alternative to antibiotics and isotretinoin.

This study found that antiandrogenic pretreatment with combined oral contraceptives did not improve ovulation and pregnancy outcomes compared to direct letrozole induction in women with PCOS.

This study found that eflornithine 15% cream reduced unwanted facial hair growth more effectively than a placebo in women with hirsutism, but hair growth returned to pretreatment levels within 8 weeks of stopping treatment.

In this study, researchers reported that both progestin-only injectable contraceptives, DMPA-IM and NET-EN, significantly decreased serum testosterone and SHBG levels among HIV-negative women in South Africa, yet this did not explain prior findings of no reduction in risky sexual behavior or sexual function.

This study found that one year of antiandrogen treatment with spironolactone significantly decreased bone mineral density in young women with androgen excess.

In male mice and rats, this study found that 17α-estradiol improves metabolic health by acting through estrogen receptor α, suggesting a potential target for treating chronic diseases in male mammals.

This study found that oral contraceptives, particularly those combining ethinyl estradiol with progestins like drospirenone and cyproterone acetate, are effective in treating androgen-related skin conditions such as acne, hirsutism, and androgenetic alopecia by reducing excess androgens and sebum production.